Index to Volume 3: Subject

Acetylcholine
  endothelium-dependent vasodilation of, 5–9
  membrane hyperpolarization and, 242–245
Acidic fibroblast growth factor
  α-actin gene expression and, 40–41
  cardiac gene activation, 38, 39
  myocardial cell growth and, 40
  in vitro release of, 16
Acidosis, in spontaneously hypertensive rat, 314–318
α-Actin gene expression, 40
Acyl coenzyme A-cholesterol acyltransferase, 268–269
Adenosine, angiogenesis and, 11–16
Adrenal cortex, angiotensin II receptor of, 192–203
β Adrenergic blockers, 39
α-Adrenoreceptor agonists
  centrally acting, 369
  effects of pertussis and cholera toxins on, 197–203
α-Adrenoreceptors, 223–227
β-Adrenoreceptors, 223–227
Aging, serotonin and, 105
Amplification phenomenon, of serotonin, 103–104
Angiogenesis
  adenosine and, 11–16
  dipyridamole and, 15–16
  HBGF family/interleukin-1 and, 403
Angiography, of polyarteritis nodosa, 421
Angiotensin
  cardiac actions of, 30–35
  vascular smooth muscle growth control and, 25–28
Angiotensin-converting enzyme inhibitors
  antiproliferative activity, 28
  glucose metabolism and, 369
  hemodynamic effects, 117–122
  lipid profile and, 369
Angiotensin II
  cardiovascular growth regulation and, 22–24
  direct pressor stimulatory actions, 20
  proto-oncogene expression and, 26
  smooth muscle extracellular matrix synthesis and, 271–275
  vascular hypertrophy and, 404
  vascular smooth muscle and, 25–26
  vessel wall, 28
Angiotensin II receptor, characterization of, 192–196
Antihypertensives. *See also specific antihypertensives*
  differential effects in atherosclerosis, 382–388
Antineutrophil cytoplasmic autoantibodies, 419
Aorta
  bradykinin-activated K+ channels, 246–249
  endothelium dependent contractions, 251–255
  phospholipase activation, 161–166
Apolipoproteins, 354
Arterial fat deposition, 268–269
Arterial smooth muscle, organelle organization, 187–190
Arterial wall, in hypertension, 25
Arteriolar constriction, endothelin-induced, 55
Arteriosclerosis, hypoxia and vascular muscle tone, 140–147
Atherogenic lipoprotein prototype, 355
Atherosclerosis
  causes of, 352–361
  fat deposition in, 268–269
  hypertension and, 371–379
  serotonin and, 103, 104–105
Atrial natriuretic factor, 38, 39
Basic fibroblast growth factor (bFGF)
  angiogenesis and, 12–16
  angiotensin and, 27
  cardiac gene activation, 38, 39
  fetal cardiac gene expression and, 39–42, 41–42
  myocardial cell growth and, 40–41
  skeletal α-actin transcription in cardiac myocytes and, 41
Blood flow
  angiogenesis and, 16
  to small intestines, 55–56
Blood pressure
  angiotensin-converting enzyme inhibition and, 117–122
  endothelin-1 and, 57–59
  in transgenic rats, 50–53
  variability, cardiovascular pathophysiology and, 363–364
Blood vessel walls, 371
Bovine retractor penis inhibitory factor (BRPIF), 68
Bradykinin
  cyclic stretching and, 61–66
  potassium ion channel activation, 246–249
Brain ischemia, serotonin and, 105–106
Buerger's disease, 425–427
Caffeine, vascular smooth muscle calcium stores and, 154–160
Calcitonin-gene-related peptide, 150–153
Calcium
  caffeine-sensitive stores, in vascular smooth muscle, 154–160
  extracellular acidosis in hypertension and, 314–318
  mobilization, in hypertension, 205–213
  phorbol-ester-induced mesenteric artery contractions, 256–260
  plasma membrane malfunction in hypertension and, 178–180
  ryanodine and, 167–172
  sensitivity, 174–177, 181–185
  in vascular muscle cells, 181–185, 261–266
Calcium antagonists
  antiatherosclerosis clinical trials, 392–400
  glucose metabolism/lipid profiles and, 369
Calcium ion hypothesis, in hypertension, 219–227
Calmodulin, 181–185
Canine femoral artery, phosphatidylinositol hydrolysis, 1–4
Canine kidney tubular epithelial cell line, 403
Canine mesenteric artery, ryanodine and, 167–172
Capillary formation, 403
Captopril, 23, 369
Cardiac α actin promoter, 38
Cardiac hypertrophy, 38
Cardiac mass, angiotensin-converting enzyme inhibition and, 117–122
Cardiac-specific genes, 38
Cardiovascular diseases, serotonin and, 103–106
Cardiovascular risk factors, hypertension and, 368–369
Catecholamines, 39
Cation flux, 371
Cell culture techniques, current and future applications, 403–405
Cell cycle, flow cytometric analysis of, 406–411
Cell differentiation, 38

Cell lines for hypertension research, 403
Cell membrane
bradykinin-activated K+ channels and, 246–249
calcium channel hypothesis and, 219–222
humoral factors of, 242–245
malfunction, in hypertension, 219–222
potassium channels, 150–153
red cell transport, clonidine sensitivity in hypertension and, 285–288
Cell proliferation, 406–411
Cerebrovascular disorders
arterial fat deposition in, 268–269
phorbol-ester-induced contractions and, 256–260
Cholera toxin, G-protein function and, 197–203
Cholesterol, total serum, 359–360
Cholesterol acyltransferase, 268–269
Cigarette smoking, thromboangiitis obliterans and, 426
Circadian rhythm, blood pressure variability and, 363–364
Clonidine sensitivity, 285–288
Cloning, molecular
of angiotensin II receptor, 192–196
of human endothelin receptor, 303–307
stretch-induced proto-oncogene expression, 290–296
Collagen, in ventricular hypertrophy, 44–45
Collateral circulation, serotonin and, 104
Computed tomography, of polyarteritis nodosa, 421–422
Coronary aneurysms, in Kawasaki disease, 428, 429
Coronary heart disease
hypoxia and vascular muscle tone in, 140–147
multiple risk factors, synergism of, 359, 360
non-lipid-related risk factors, 356–359
risk factors, 352–361
Coronary vessels, 242–245
Cyclic stretching, 61–66
Cytoplasmic proteins, calcium sensitivity and, 174–177, 181–185
Deep vein thrombosis, 432–438
Diabetes, coronary risk and, 358–359
Diltiazem, 369
Dipyridamole, angiogenesis and, 15–16
DNA
angiotensin II receptor characterization, 192–196
growth-factor stimulated synthesis, 308–313
in human endothelin receptor, 303–307
polyploidy and, 25
proto-oncogene expression and, 290–296
Duplex ultrasound scanning, of deep vein thrombosis, 432–438
Dyslipidemia, hypertension and, 363–369, 371–379
Echocardiography, 429
EDRF. *See* Endothelium-dependent relaxing factor
Endothelial cells
dysfunction, in myocardial ischemia, 5–9
seeding, 124–133
thrombomodulator production in, 124–133
Endothelin-1
intestinal microvasculature and, 55–59
phospholipase activation and, 161–166
Endothelin receptor, cloning of, 303–307
Endothelium, vascular
atherosclerosis and, 140–147
bradykinin-activated K+ channels in, 246–249
cloning of endothelin receptor, 303–307
contractions, noradrenaline-induced, 251–255
in endocardial infiltrates, 113–116
humoral factors, membrane hyperpolarization and, 242–245
physiologic functions of, 371–379
Endothelium-dependent contractions, 251–255
Endothelium-dependent relaxing factor
release, reperfusion and, 5–8
vs. neutrophil-derived relaxing factor, 68–74
Endothelium-dependent vasodilation, after myocardial ischemia, 5–9
Environmental susceptibility, in hypertension, 297–301
Epidermal growth factor-urogastrone, 308–313
Epinephrine, phospholipase activation and, 161–166
Erythrocyte transport, clonidine sensitivity and, 285–288
Essential thrombocytosis, platelet factor 4 release and, 134–138
Excitation-contraction coupling
calcium channel hypothesis and, 219–222
calcium mobilization and, 205–213, 229–233
calcium sensitivity and, 174–177
intracellular calcium in vascular smooth muscle and, 261–266
phorbol ester and, 256–260
ryanodine and, 167–172
in vascular smooth muscle, 154–160
Extracellular matrix synthesis, 271–275
Fat deposition, 268–269
Flow cytometry, 406–411
Fluo-3, 261–266
fos oncogenes, 26–27
Framingham Heart Study, 352–361
Fura-2
extracellular acidosis and, 314–318
intravascular calcium and, 261–266
Furosemide, Na/K+ transport and, 61–66
Genes, in cell growth, 26
Genetics, environmental susceptibility in hypertension and, 297–301
Giant cell arteritis, 422–425
Glibenclamide, 150–153
Glomerulosclerosis, 404
Glucose abnormalities, 368–369
Glucose intolerance, hypertension and, 366–369
Glyburide, 150–153
Glycosaminoglycans, platelet factor 4 release and, 134–138
G-protein function, 197–203
Growth substances, 308–313
Guanosine 5′-0-(3-thiotriphosphate)
calcium mobilization and, 205–213
calcium sensitization and, 181–185
Guinea pig, caffeine-sensitive stores in, 154–160
HBGF (heparin-binding fibroblast growth factor), 403
HDL cholesterol, 353–354, 360–361
Heart
ischemia-reperfusion study, 5–9
quinapril and, 117–122
Heat shock proteins, 297–301
Hemodynamics
of angiogenesis, 16

endothelin-1 induced changes, 55–59
quinapril and, 117–122
Heparin, platelet factor 4 release and, 134–138
Heparin-binding fibroblast growth factor (HBGF), 403
High endothelial venules, 113–116
HLA-A9, 426
HLA-B5, 422, 426
HLA-DR4, 424
Homing, 113–116
HSP70 gene, 297–301
5-HT. *See* Serotonin
5-HT2 antagonists, in vascular disorders, 106–108
5-HT2 receptors, 102–104
Hypercholesterolemia, 103–105
Hyperinsulinemia
hypertension and, 369
hypertriglyceridemia and, 356
obesity and, 356–357
Hyperlipidemia, serotonin and, 103, 104–105
Hyperpolarization
atherosclerosis and, 140–147
bradykinin-activated K+ channels and, 246–249
calcitonin-gene-related peptide and, 150–153
calcium channel hypothesis and, 219–222
calcium mobilization and, 205–213
endothelial humoral factors and, 242–245
Hypertension
arterial wall changes in, 25
atherosclerosis and, 371–379
calcium channel hypothesis and, 219–227
calcium mobilization in, 205–213
clonidine sensitivity and, 285–288
coronary risk and, 357
environmental susceptibility and, 297–301
exponential growth phase in, 406–411
heart functional/structural changes in, 364–368
human endothelin receptor and, 303–307
kidney functional/structural changes in, 364–368
model. *See* Spontaneously hypertensive rats (SHR)
nitroxidergic vasodilator nerve function and, 235–240
pathogenesis of, 371–379
pertussis and cholera toxin effects, 197–203
plasma membrane malfunction, 178–180
platelets abnormalities in, 277–283
renin-angiotensin system inhibition and, 23
risk factors, 363
serotonin and, 103, 105
syndrome of, 364
therapy for, 368–369
in transgenic rats, 50–53
Hypertriglyceridemia
hyperinsulinemia and, 356
insulin resistance and, 356
Hypoxia
arteriosclerosis and, 140–147
serotonin and, 105
ICI 169369, 107
Iloprost, 140–147
Immune recognition phenomena, 113
Inositol triphosphate
intracalcium stores in vascular smooth muscle and, 154–160
Insoitol triphosphate
calcium mobilization and, 205–213
intracellular calcium in vascular smooth muscle and, 261–266
phospholipase activation and, 161–166
ryanodine and, 167–172
Insulin abnormalities, 368–369
Insulin resistance
hypertension and, 366–369
hypertriglyceridemia and, 356
Interleukin-1
Intermediate-density lipoprotein, 354
Intracellular signaling, 403
Intravital microscopy, of endothelin-1-induced hemodynamic changes, 55–59
Ion channels. *See also* Potassium channels
calcium channel hypothesis and, 219–222
Ion exchange, 285–288
Ion transport systems, 61
Irindalone, 107
Ischemia
collateral development in, 11
myocardial, 5–9
serotonin and, 105–106
Isometric tension
atherosclerosis and, 140–147
stretch-induced proto-oncogene expression and, 290–296
jun oncogenes, 26
Kawasaki disease, 427–429
Ketanserin, 107
Kidney
angiotensin II receptor, 192–196
clonidine sensitivity and, 285–288
environmental susceptibility in hypertension and, 297–301
KT-362, 1–4
Laminin, site-directed mutagenesis, 403
LDL cholesterol, 352–355, 360
Lipids, coronary risk and, 352–356
Liver stem cells, 403
Low density lipoprotein (LDL), 354–355
LY 281-067, 107
LY 53857, 107
Magnesium, 2999–233
Martorell sign, 427
mas oncogene product. 23–24
MDCK cell line, 403
MDL 26508, 107
MECA-79 (murine endothelial cell antigen-79), 113
Membrane potentials
atherosclerosis and, 140–147
calcium channel hypothesis and, 219–222
calcium mobilization and, 205–213
membrane hyperpolarization and, 242–245
Mesangial hypertrophy, 404
Mesenteric arteries
phorbol-ester-induced contractions, 256–260
ryanodine and, 167–172
suppression of nitroxidergic vasodilator nerve function and, 235–240
Microaneurysms, in polyarteritis nodosa, 421
Microcirculation, endothelin-1, 55–59
Mitogenesis, adenosine and, 11–16
Molecular biological techniques, current and future applications, 403–405
Mucocutaneous lymph node syndrome, 427–429
Muscle, smooth vascular
activated acyl coenzyme A-cholesterol acyltransferase and, 268–269
agonists in, 229–233
angiotensin II and, 25–26
caffeine sensitive calcium stores in, 154–160
calcium channel hypothesis and, 178–180
calcium sensitization of, 181–185
cultured cells, 404, 406–411
extracellular matrix synthesis, 271–275

growth control, angiotensin and, 25–28
growth-factor-stimulated DNA synthesis, 308–313
membrane hyperpolarization, 242–245
organelle organization, 187–190
phospholipase activation in, 161–166
ryanodine and, 167–172
sarcolemmal calcium, in hypertension, 261–266
tone, in arteriosclerosis, 140–147
vasodilatory response, 150–153
Muscle contraction
deterioration, by noradrenaline, 251–255
extracellular sodium and, 229–233
phorbol-ester-induced, 256–260
phospholipase activation and, 161–166
Myocardial infarction, circadian rhythm and, 364
Myocardial ischemia
circadian rhythm and, 364
endothelial function recovery, 5–9
Myocardium
nonmyocyte compartment, 44–45
remodeling, 45–48
Myocyte(s)
acidic fibroblast growth factor and, 40
growth, 20, 44
hypertrophy, 39
induction of fetal gene expression, 39–40
skeletal α-actin transcription, 41
stretch-induced proto-oncogene expression, 290–296
workload, 44
β Myosin heavy chain, 38, 39
Naftidrofuryl, 107–108
Na+/K+ ATPase, 39
National Cholesterol Education Program (NCEP), 359–361
Neutrophil-derived relaxing factor (NDRF), 68–74
N*SU1*G*SU0*-Nitro-L-arginine, 235–240
Nitrate, vascular relaxing activity, 68–74
Nitric oxide
deterioration of muscle contraction and, 251–255
suppression of nitroxidergic vasodilator function, 235–240
vascular relaxing activity, 68–74
Nitrite, vascular relaxing activity, 68–74
Nitroprusside, vascular relaxing activity, 68–74
Nitroxidergic vasodilator nerve function, suppression of, 235–240
Nonspecific vascular disease, 429
Noradrenaline, 251–255
Norepinephrine
caffeine-sensitive intracalcium stores and, 154–160
muscle contraction deterioration and, 251–255
phospholipase activation and, 261–266
Obesity
coronary risk and, 358
hyperinsulinemia and, 356–357
Oncogenes, 404
Organelles, smooth vascular muscle, 187–190
Ouabain, Na/K+ transport and, 61–66
PDGF. *See* Platelet-derived growth factor
PDGF (platelet-derived growth factor), 27
Peripheral lymph node addressin, in endocardial infiltrates, 113–116
Peripheral vascular disease, serotonin and, 106
Pertussis toxin
calcitonin-gene-related peptide and, 150–153
pressor effects and, 197–203
pH, extracellular acidosis in hypertension and, 314–318
Phorbol-ester-induced mesenteric artery contractions, 256–260
Phorbol myristate acetate (PMA), 27
Phosphatidic acids, 161–166
Phosphatidylinositol hydrolysis, vasodilation and inhibition, 1–4
Phospholipase
activation of, 161–166
calcium mobilization and, 205–213
Phospholipase C, 26
Plasma renin activity, hypertension and, 368
Platelet aggregation
extracellular acidosis in hypertension and, 314–318
serotonin and, 102–103
Platelet-derived growth factor
angiotensin II and, 27
DNA synthesis in SHRs and, 308–313
extracellular matrix synthesis and, 271–275
Platelet factor 4 release, heparin-induced, in thrombocytosis, 134–138
Platelets, hypertensive, 277–283
Polyarteritis nodosa
clinical presentation, 419–420
diagnosis of, 421–422
etiology of, 420–421
laboratory features, 420
Polycythemia vera, platelet factor 4 release and, 134–138
Potassium
ryanodine and, 167–172
transport, cyclic stretching and, 61–66
Potassium channels
bradykinin-activated, 246–249
calcitonin-gene-related peptide and, 150–153
calcium mobilization and, 205–213
membrane hyperpolarization and, 242–245
phospholipase activation and, 161–166
sarcolemmal calcium in hypertension, 261–266
vasodilatory response to calcitonin-gene-related peptide and, 150–153
Prazosin, 369
Pressurized arteriography, of resistance vessels, 413–418
Proliferation, vascular, serotonin and, 103
Prostacyclin, production in endothelial cell cultures, 124–133
Protein kinase C
angiotensin II and, 26–27
growth-factor stimulated DNA synthesis and, 308–313
Protein kinases
calcium sensitization and, 181–185
intraplatelet, in hypertension, 277–283
phospholipase activation and, 161–166
Proteins, cytosoluble, calcium sensitivity and, 174–177
Proto-oncogenes
in hypertrophic response, 26–27
stretch-induced expression, in cardiac myocytes, 290–296
Quilty effects, 113–116
Quinapril, hemodynamic and cardiac effects of, 117–122
Red cell ion transport, clonidine sensitivity and, 285–288

Regional hemodynamics, angiotensin-converting enzyme inhibition and, 117–122
Renal epithelial cell line (LLC-PK), 404
Ren-2 gene, 50–53
Renin, in transgenic rats, 50–53
Renin-angiotensin system, 23
Renin-secreting tumors, 405
Reperfusion, endothelium-dependent relaxing factor release and, 5–8
Resistance vessel dimensions, measurement precision, 413–417
Retroviral promoter trap system, 404
Ritanserin, 107
Ryanodine
  caffeine-sensitive calcium stores and, 154–160
  potassium and adrenergic stimulation, effects on, 167–172
Sarcoplasmic reticulum
  calcium mobilization and, 205–213
  intracellular calcium in hypertension and, 261–266
  ryanodine and, 167–172
  in smooth muscle cell, 187–190
Secondary thrombocytosis, platelet factor 4 release and, 134–138
Serial passage, 124–133
Serotonin
  aging and, 105
  amplification phenomenon, 103–104
  in cardiovascular diseases, 103–106
  collateral circulation and, 104
  in ischemic diseases, 105–106
  peripheral vascular disease and, 106
  pharmacologic effects in vascular bed, 102–103
  vascular bed sources, 101
Serotonin receptors, 102–104
Shark rectal gland epithelial cells, 403
SHR. *See* Spontaneously hypertensive rats (SHR)
Skeletal α-actin, 38–41
Sodium
  transport
    cyclic stretching and, 61–66
    hypertension and, 285–288
  vascular contractility and, 229–233
Sodium-potassium pump, 61
Spontaneously hypertensive rats (SHR)
  acyl coenzyme A-cholesterol acyltransferase activity in, 268–269
  adrenoreceptor subtypes, 223–227
  captopril and, 23, 25
  endothelium dependent contractions, 251–255
  exponential cell growth phase, 406–411
  extracellular acidosis in, 314–318
  extracellular matrix synthesis and, 271–275
  growth-factor-stimulated DNA synthesis, 308–313
  intracellular calcium in vascular muscle cells, 261–266
  phorbol-ester-induced mesenteric artery contractions, 256–260
  quinapril and, 117–122
Stress, in hypertension, 297–301
Striated α-actin genes, 40–41
Superoxide dismutase, endothelial dysfunction and, 5–9
SV40 T antigen, 404
Takayasu's arteritis, 424–425
Temperature-sensitive mutant virus of SV40, 404
Temporal arteritis, 422–424
Tenascin, 271–275
Thromboangiitis obliterans, 425–427
Thrombocytosis, heparin-induced platelet factor 4 release and, 134–138
Thrombospondin, 271–275
Thromboxane, production in endothelial cell cultures, 124–133
Thymidine, 308–313
Thyroid hormone, 39
Tissue plasminogen activator, production in cell cultures, 124–133
Tissue-specific cell-cell adhesion, 113
TMB-8, 1–4
*TNF*α gene, 297–301
Transforming growth factor-β 1, angiotensin-II induced smooth muscle growth, 27–28
Transforming growth factor β 1, fetal cardiac gene expression and, 39–42
Transgenic animals, 404
Triglycerides, coronary risk and, 354–355
Tropomyosin, intraplatelet, in hypertension, 277–283
Tumor necrosis factor, 297–301
Vascular endothelial cells, 61
Vascular graft seeding, 124–133
Vascular hypertrophy, 25
Vascular leakage, serotonin and, 103
Vascular muscle tone, arteriosclerosis and, 140–147
Vascular resistance, quinapril and, 117–122
Vasculitides
  giant cell arteritis, 422–425
  nonspecific vascular disease, 429
  pathogenic mechanisms, 419
  polyarteritis nodosa, 419–422
  terminology, 419
  thromboangiitis obliterans, 425–427
Vasoconstriction, serotonin and, 102
Vasodilation
  angiogenesis and, 16
  arteriosclerosis and, 140–147
  endothelium-dependent, after myocardial ischemia, 5–9
  nitroxidergic, 235–240
  of phosphatidylinositol hydrolysis, 1–4
  potassium channels and, 150–153, 246–249
Vasopressins, 197–203
Ventricular hypertrophy
  collagen in, 44–45
  coronary risk and, 357–358
  development of, 20–21
  hypertension and, 364–366
  quinapril and, 117–122
  reversal of, 369
  selective induction of, 39
Very-low-density lipoprotein (VLDL), 354
Wall-to-wall lumen ratio, 413–417
Wegener's granulomatosis, 419
Wistar-Kyoto rats (WKY)
  acyl coenzyme A-cholesterol acyltransferase activity in, 268–269
  captopril and, 23
  cell cycle of, 406–411
  quinapril and, 117–122
ZK 33839, 107

Index to Volume 3: Author

Adams, Laurel M., 68
Adragna, N.C., 61
Akata, T., 205
Ando, Katsuyuki, 117
Ansell, Jack E., 124
Aoki, Kyuzo, 223
Applegate, William B., 371

Arai, Hiroshi, 303
Armstrong, Susan J., 68

Bachmann, S., 50
Bader, M., 50
Baker, Kenneth M., 30
Bardhan, Smriti, 192
Bergelin, Robert, 432
Bhalla, Ramesh C., 308
Bian, Ka, 219
Biro, Sadatoshi, 11
Bohr, David F., 178
Bond, M. Gene, 392
Borghetti, Alberico, 174
Bose, Ratna, 314
Bourreau, J.-P., 167
Brilla, Christian G., 44
Bruschi, Giacomo, 174
Bruschi, Maria E., 174
Bühler, Fritz R., 139, 271, 277
Butcher, Eugene C., 113

Carr, Albert A., 392
Casscells, Ward, 11
Castelli, William P., 352
Cella, Giuseppe, 134
Chaki, Shigeyuki, 192
Chakrabarti, Jai, 419
Chen, Guifa, 242
Chien, Yongwei, 117
Chopra, Paramijit S., 419
Chow, King-Lau, 38
Crabos, Maryse, 277

Daniel, E. E., 167
Dominiczak, Anna F., 178
Dzau, Victor J., 25, 316, 351, 382

Endo, Makoto, 154
Epstein, Stephen E., 11
Erne, Paul, 261, 277

Fabbro, Doriano, 277
Flack, John, 392
Frohlich, Edward D., 20, 117
Frohly, Pierre, 285
Fujimoto, Seigo, 223
Fukumura, Dai, 55
Furspan, Philip B., 150

Ganten, D., 50
Ganten, U., 50
Garay, Ricardo, P., 285
Geisbuhler, Brinda B., 161
Gibbons, Gary H., 25
Gross, Garrett J., 1

Hajem, Said, 285
Hamada, Masanori, 406
Hamet, Pavel, 297
Harris, E. L., 406
Hasegawa, Mamoru, 192
Heizmann, Claus W., 277
Hermsmeyer, Kent, 139, 219, 261
Hetzer, R., 140
Hillard, Cecilia J., 1
Holloway, Deborah A., 68
Hosoda, Kiminori, 303
Hosogi, Yoshiko, 251
Hruz, Paul W., 1
Hsueh, Willa A., 403

Iino, Masamitsu, 154
Iino, Tomoya, 11
Imber, Roland, 277
Imura, Hiroo, 303
Inagami, Tadashi, 192
Inoue, R., 205
Itoh, Hiroshi, 25
Iwai, Naoharu, 192

Jamieson, Michael J., 413
Janicki, Joseph S., 44
Jones, Allan W., 161
Jones, Susan B., 161

Kamouchi, M., 205
Kandarpa, Krishna, 419
Khoury, Sleman A., 392
Kitamura, K., 205
Kitamura, Yoshihiko, 235
Klassen, Valerie A., 124
Klir, Pavel, 297
Komuro, Issei, 290
Kong, Dewen, 297
Konishiih, Fumiko, 192
Kren, Vladimir, 297
Kunes, Jaroslav, 297
Kuriyama, H., 205
Kurose, Iwao, 55
Kwan, C. Y., 167

Land, Robert, 261
Lee, M., 50
Lefer, Allan M., 5
Li, Chen, 22
Li, Jian-ming, 124
Lin, Michael C., 403
Little, Sally A., 187
Liu, Yu, 161

Mackie, Eleanor J., 271
McGuffee, Linda J., 187
McManus, Bruce M., 113
Manabe, Yoshihisa, 181
Mandell, Valerie, 419
Manzo, Richard A., 432
Markel, Arie, 432
Matsuda, Tomohiro, 223
Menconi, Michael J., 124
Mercure, Juanita, 187
Mercuri, Michele, 392
Millar, J. A., 406
Miura, Soichiro, 55
Miwa, Kyoko, 242, 246
Moriyama, Kenzo, 256
Müller, J., 140
Mullins, J. J., 50
Murakami, S., 268
Murray, John J., 192

Nakagawa, Osamu, 303
Nakanishi, Shigetada, 303
Nakao, Kazuwa, 303
Nara, Y., 268
Nichols, Fenwick T., 392

Ogawa, Yoshihiro, 303
Okamura, Tomio, 235
Ollivier, Jean-Pierre, 285
Omoigui, Nowamagbe, 382
Ontiveros, Jorge A., 413

Paolini, Rossella, 134
Parker, Thomas, G., 38
Patel, Parita, 314
Pegram, Barbara L., 117
Prakash, Om, 22
Pratt, Richard E., 25
Pravenec, Michal, 297

Rapin, Jean R., 101
Re, Richard, 22
Rimele, Thomas J., 68
Rohrer, Michael J., 124

Saida, Kooichi, 181
Sasaki, Katsutoshi, 192
Sato, Koichi, 139
Schaarschmidt, J., 140
Schnalke, F., 140
Schneider, Michael D., 38
Schwartz, Robert J., 38
Scott-Burden, Timothy, 271
Seki, Hitomi, 181
Sekizuka, Eiichi, 55
Senn, Nathalie, 285
Serizawa, Hiroshi, 55
Sharma, Ram V., 308
Sharma, Shubhra, 314
Shetty, Suraj S., 229
Shimamura, Keiichi, 251, 256
Shukla, Shivendra D., 161
Siegel, G., 140
Simpson, F. O., 406
Stevanato, Francesco, 134
Strandness, D. Eugene Jr., 432
Strauss, William E., 134
Streeter, Phillip R., 113
Sturm, Robert J., 68

Suematsu, Makoto, 55
Suga, Shin-ichi, 303
Sun, Yu-Lin, 297
Sunano, Satoru, 251, 256
Suzuki, Hikaru, 242, 246

Tabrizchi, Reza, 197
Tashiro, Hirokazu, 55
Toda, Noboru, 235
Tremblay, Johanne, 297
Triggle, Chris R., 197
Tsao, Philip S., 5
Tsuchiya, Masaharu, 55

Vanhoutte, Paul M., 271
Veronese, Patrizia, 134

Webb, R. Clinton, 150, 178
Weber, Karl T., 44
Weber, Michael A., 363
Weichman, Barry M., 68
Weiss, George B., 229
Wheeler, H. Brownell, 124
Wiernsperger, Nicolas, 101
Winters, Gayle L., 113
Woodtli, Thomas, 277

Xiong, Z., 205

Yamakado, Toshi, 277
Yamamoto, Tatsuro, 154
Yamamoto, Yoshimichi, 242, 246
Yamano, Yoshiaki, 192
Yamazawa, Toshiko, 154
Yamori, Y., 268
Yazaki, Yoshio, 290
Ye, Yuling, 113

Zerbe, Tony R., 113
Zhao, Y., 50
Zimmerman, F., 50